Mark T Iwicki
CIK 1415537 · Chief Executive Officer · last filed 2026-07-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.9K
Companies
11
Total Filings
85
Lifetime Open-Market Net
$131.7K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QTTB | Director | — | $15.71 | — | $0 | 5 | 2026-07-21 |
| IKT | Chief Executive Officer | — | $2.31 | — | $0 | 4 | 2026-01-07 |
| Merus N.V. (MRUS) Delisted | Director | 0 | $90.00 | $0 | $0 | 8 | 2025-12-12 |
| Akero Therapeutics, Inc. (AKRO) Delisted | Director | 0 | $54.65 | $0 | $0 | 7 | 2025-12-09 |
| KALA | Director | 2,071 | $0.66 | $1.4K | -$488.3K | 25 | 2025-10-24 |
| Third Harmonic Bio, Inc. (THRD) Delisted | Director | — | $5.38 | — | $0 | 4 | 2024-06-10 |
| Jade Biosciences, Inc. (AVTE) Delisted | Director | — | $93.80 | — | $0 | 4 | 2024-06-07 |
| PULM | Director | 1,535 | $1.68 | $2.6K | $0 | 8 | 2021-02-01 |
| COLL | Director | 0 | $35.90 | $0 | $300.0K | 7 | 2020-10-14 |
| Aimmune Therapeutics, Inc. (AIMT) Delisted | Director | 20,000 | — | — | $320.0K | 1 | 2015-08-11 |
| SEPRACOR INC /DE/ (SEPR) Delisted | EVP & Chief Commercial Officer | 122,334 | — | — | $0 | 4 | 2009-10-19 |
Recent Filings · Page 3 of 9
85 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-02-19 | IKT | Grant (A) | — | $0 | EDGAR |
| 2025-01-07 | KALA | Mixed | +16,321 | -$44.1K | EDGAR |
| 2025-01-06 | KALA | Notice (144) | −5,779 | -$44.1K | EDGAR |
| 2024-06-27 | KALA | Sell (S) | −15,168 | -$72.0K | EDGAR |
| 2024-06-24 | KALA | Notice (144) | −14,210 | -$69.6K | EDGAR |
| 2024-06-11 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-10 | Third Harmonic Bio, Inc. (THRD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | Jade Biosciences, Inc. (AVTE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-03 | KALA | Sell (S) | −7,392 | -$45.0K | EDGAR |
| 2024-05-31 | KALA | Notice (144) | −7,392 | -$45.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.